Treatment of Midgut Neuroendocrine Tumors

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.

In this video, Jonathan Strosberg, MD, of the Moffitt Cancer Center, discusses current options for the treatment of midgut neuroendocrine tumors; highlights results of the NETTER-1 trial, which showed improved progression-free survival with lutetium-177 (177Lu)–Dotatate in this patient population; and discusses the use of radionuclide therapy in other types of neuroendocrine tumors.

Results of the phase III NETTER-1 trial were recently published in the New England Journal of Medicine, showing that treatment of well-differentiated, metastatic midgut neuroendocrine tumors with 177Lu–Dotatate improved response rates (18% vs 3%) and improved the estimated rate of progression-free survival at 20 months (65.2% vs 10.8%).

Dr. Strosberg spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held last month in San Francisco.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Related Content
MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Roman Fabbricatore
April 23rd 2025
Article

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC

Fruquintinib Combo Exhibits Manageable Safety Profile in Pretreated mCRC

Tim Cortese
April 22nd 2025
Article

Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years and older.

Pancreatic/Colorectal Adenocarcinoma Rates Have Increased in Young Adults

Roman Fabbricatore
April 15th 2025
Article

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

Robot-Assisted Esophagectomy Achieves “Best Outcome Data” in Study

Robot-Assisted Esophagectomy Achieves “Best Outcome Data” in Study

Tim Cortese
April 14th 2025
Article

Robot-assisted minimally invasive esophagectomies with anastomotic technique were completed without complications or mortality in a majority of patients.